Skip to content

Prospective Italian Validation of SMS in Patients With Suspected Acute Stroke

Prospective Italian Multicenter Study for the Validation of the Stroke Mimics Score (SMS) in Patients With Suspected Acute Stroke

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07601659
Acronym
PIVA-SMS
Enrollment
1000
Registered
2026-05-22
Start date
2026-06-01
Completion date
2027-06-01
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke, Cerebrovascular Event, Intracerebral Hemorrhage, Stroke, TIA (Transient Ischemic Attack)

Brief summary

The overall objective of the study is to prospectively validate the diagnostic accuracy of the Stroke Mimics Score (SMS). This score is calculated using information collected at the time of the patient's arrival in the Emergency Department (triage) and may assist clinicians in distinguishing between: 1. cerebrovascular events (ischemic stroke, intracerebral hemorrhage, and transient ischemic attack \[TIA\]), 2. stroke mimics (i.e., conditions that present with stroke-like symptoms but without actual infarction of brain tissue). In addition, the study aims to compare its results with other existing tools and to evaluate its performance across different patient groups. Specifically, the present research seeks to generate data on the reliability of the SMS tool in providing an accurate diagnosis.

Interventions

None listed

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years at the time of presentation to the Emergency Department. * Presentation to the Emergency Department with a clinical suspicion of acute stroke, identified at nursing triage and/or through activation of the stroke pathway. * Presentation to the Emergency Department during the 6-month prospective enrollment period. * Feasibility of real-time collection of the data required to calculate the Stroke Mimics Score (SMS), including: age, systolic blood pressure, presence/absence of seizure at onset, presence/absence of headache at onset, presence/absence of confusion at onset, presence/absence of syncope at onset, presence/absence of isolated sensory deficit, presence/absence of motor deficit, history of coronary artery disease, history of prior stroke or transient ischemic attack (TIA). * Availability of a final hospital discharge diagnosis at the end of hospitalization or Emergency Department observation. * Signed informed consent from the patient or caregiver. If the patient is unconscious upon arrival at the Emergency Department, deferred consent will be applied.

Exclusion criteria

* Age \< 18 years. * Inability to fully collect the data required to calculate the Stroke Mimics Score (SMS). * Absence of a clearly defined final hospital discharge diagnosis. * Voluntary discharge, transfer, or death before completion of the diagnostic workup, in the absence of a reliable diagnosis. * Repeated Emergency Department visits for the same clinical event (only the first visit will be considered).

Design outcomes

Primary

MeasureTime frameDescription
The rate of accuracy of Stroke Mimics Score (SMS)through study completion, about 1 yearDiagnostic accuracy of the Stroke Mimics Score (SMS) in discriminating between: 1. cerebrovascular events (CVE), 2. stroke mimics (SM), assessed by: Area Under the Receiver Operating Characteristic Curve (AUROC). The AUROC will be calculated with a 95% confidence interval. An AUROC value significantly higher than 0.70 will be considered indicative of an acceptable discriminative ability of the score.

Secondary

MeasureTime frameDescription
Analyses across clinical subgroupsthrough study completion, about 1 yearTo evaluate sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), score calibration, the performance of the grouped version (SMSg), comparison with FABS and TMS, and analyses across clinical subgroups.

Contacts

CONTACTGiovanni Frisullo
giovanni.frisullo@policlinicogemelli.it+393476612284
PRINCIPAL_INVESTIGATORGiovanni Frisullo

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026